Compare Elder Pharma with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA PROCTER & GAMBLE HEALTH ELDER PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x -0.2 17.0 - View Chart
P/BV x 0.1 6.8 1.5% View Chart
Dividend Yield % 0.0 6.9 -  

Financials

 ELDER PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
PROCTER & GAMBLE HEALTH
Dec-18
ELDER PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs3803,549 10.7%   
Low Rs1881,301 14.4%   
Sales per share (Unadj.) Rs491.2511.4 96.0%  
Earnings per share (Unadj.) Rs-3.261.3 -5.2%  
Cash flow per share (Unadj.) Rs14.474.0 19.5%  
Dividends per share (Unadj.) Rs0440.00 0.0%  
Dividend yield (eoy) %018.1 0.0%  
Book value per share (Unadj.) Rs376.5927.8 40.6%  
Shares outstanding (eoy) m20.5416.60 123.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.64.7 12.2%   
Avg P/E ratio x-89.339.6 -225.6%  
P/CF ratio (eoy) x19.732.8 60.2%  
Price / Book Value ratio x0.82.6 28.9%  
Dividend payout %0717.9 0.0%   
Avg Mkt Cap Rs m5,83340,257 14.5%   
No. of employees `000NA1.1 0.0%   
Total wages/salary Rs m2,1791,313 166.0%   
Avg. sales/employee Rs ThNM7,486.7-  
Avg. wages/employee Rs ThNM1,157.6-  
Avg. net profit/employee Rs ThNM897.2-  
INCOME DATA
Net Sales Rs m10,0898,490 118.8%  
Other income Rs m257244 105.2%   
Total revenues Rs m10,3468,734 118.5%   
Gross profit Rs m-7921,482 -53.4%  
Depreciation Rs m361211 171.1%   
Interest Rs m2,7560-   
Profit before tax Rs m-3,6531,514 -241.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,71366 5,659.6%   
Tax Rs m125563 22.2%   
Profit after tax Rs m-651,017 -6.4%  
Gross profit margin %-7.817.5 -45.0%  
Effective tax rate %-3.437.1 -9.2%   
Net profit margin %-0.612.0 -5.4%  
BALANCE SHEET DATA
Current assets Rs m9,24015,343 60.2%   
Current liabilities Rs m9,9981,960 510.0%   
Net working cap to sales %-7.5157.6 -4.8%  
Current ratio x0.97.8 11.8%  
Inventory Days Days4649 95.0%  
Debtors Days Days6028 210.7%  
Net fixed assets Rs m10,1241,209 837.2%   
Share capital Rs m206166 123.9%   
"Free" reserves Rs m5,58215,235 36.6%   
Net worth Rs m7,73415,401 50.2%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88217,595 130.1%  
Interest coverage x-0.3NM-  
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.5 91.4%   
Return on assets %11.85.8 203.4%  
Return on equity %-0.86.6 -12.8%  
Return on capital %22.310.3 217.5%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m3071,636 18.7%   
Fx outflow Rs m1254,368 2.9%   
Net fx Rs m181-2,732 -6.6%   
CASH FLOW
From Operations Rs m11,754-1,304 -901.5%  
From Investments Rs m-56112,697 -4.4%  
From Financial Activity Rs m-6,762-301 2,250.2%  
Net Cashflow Rs m4,43211,093 40.0%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 7.5 18.2 41.2%  
FIIs % 16.8 1.0 1,680.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 29.1 124.1%  
Shareholders   16,479 28,591 57.6%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   WOCKHARDT  J.B.CHEMICALS  SHASUN PHARMA  BIOCON   FULFORD INDIA  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Plunged 883 Points Today(Closing)

Indian share markets nosedived and registered sharp losses in today's volatile session following a strong second wave of Covid-19 in the country.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS